Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Consensus Price Target from Brokerages

Shares of Celcuity Inc. (NASDAQ:CELC) have been given a consensus rating of “Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $29.17.

Several brokerages recently commented on CELC. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Celcuity in a report on Friday, November 15th. Lifesci Capital assumed coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price on the stock. Finally, Stifel Nicolaus upped their target price on shares of Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 7th.

Celcuity Stock Performance

Shares of NASDAQ:CELC opened at $12.85 on Monday. The company has a market capitalization of $477.12 million, a price-to-earnings ratio of -5.00 and a beta of 0.76. Celcuity has a 12 month low of $11.51 and a 12 month high of $22.19. The firm’s 50-day moving average is $14.83 and its 200 day moving average is $15.81. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65.

Hedge Funds Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Quest Partners LLC boosted its stake in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after purchasing an additional 1,379 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock valued at $272,000 after acquiring an additional 1,500 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after acquiring an additional 1,600 shares during the last quarter. Acuta Capital Partners LLC lifted its position in Celcuity by 3.6% during the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after acquiring an additional 1,600 shares during the last quarter. Finally, nVerses Capital LLC purchased a new stake in Celcuity during the third quarter valued at approximately $33,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.